Vazyme Biotech
Launch date
Market cap
€913m
Enterprise valuation
€675m (Public information from Sep 2024)
Share price
CNY17.84 688105.SS
China (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.6b | 1.9b | 3.6b | 1.3b | 1.6b | 2.0b | 2.4b |
| % growth | 483 % | 19 % | 91 % | (64 %) | 22 % | 30 % | 19 % |
| EBITDA | 1.0b | 870m | 1.3b | 166m | 89.9m | 354m | 467m |
| % EBITDA margin | 66 % | 47 % | 37 % | 13 % | 6 % | 17 % | 19 % |
| Profit | 822m | 678m | 594m | (71.0m) | 212m | 313m | 365m |
| % profit margin | 53 % | 36 % | 17 % | (6 %) | 13 % | 15 % | 15 % |
| EV / revenue | - | 22.7x | 6.0x | 10.0x | 5.2x | 4.0x | 3.4x |
| EV / EBITDA | - | 48.8x | 16.1x | 77.2x | 90.1x | 22.9x | 17.4x |
| R&D budget | 126m | 230m | 396m | 339m | - | - | - |
| R&D % of revenue | 8 % | 12 % | 11 % | 26 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Angel | |
* | N/A | Series A | |
* | CNY12.0m | Series B | |
* | N/A | Series B | |
* | $78.0m | Series C | |
* | CNY550m | Series C | |
| N/A | $340m | IPO | |
| Total Funding | €141m | ||
Recent News about Vazyme Biotech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.